AstraZeneca (NYSE:AZN) is revamping its research and development divisions to improve drug development by cutting 1,600 from its global operations and focusing R&D staff in three sites including Gaithersburg, Maryland. It plans to ditch its London headquarters in favor of a new $500 million center in Cambridge in the UK by 2016. By focusing on […]
Bristol-Myers Squibb’s (NYSE:BMY) $7 billion acquisition of Amylin Phramaceuticals (NASDAQGS:AMLN) is one of the largest diabetes deals for the year to date. Given Bristol-Myers Squibb’s and AstraZeneca’s (NYSE:AZN) five-year-old diabetes drug development alliance, the latest deal stands to position them in stronger competition with Sanofi, Novo Nordisk and Merck. As part of the deal, AstraZeneca […]
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Big data’s surging tide of information on medicines, patients and outcomes is changing how pharmaceutical companies develop new drugs. Consider AstraZeneca (NYSE:AZN). The data on whether a drug will work in certain patients makes that drug more valuable, said AstraZeneca’s Dr. Steve Labkoff, head of strategic programs, research and development informations. Insurance companies don’t want […]
David Brennan's move to retire as AstraZeneca's CEO in June did not come as a surprise to those who had been urging for a change at the top over the company's drug development shortcomings. In an industry that walks a tightrope between innovation and regulation and the financial considerations that frame them, there are two critical characteristics that can undermine a CEO: being too bold or not bold enough. Brennan was a bit of both.
AstraZeneca (NYSE:AZN) has agreed to acquire a biotechnology company with a gout drug in phase 3 clinical trials for $1.26 billion, according to a company statement, in a move that will help deepen its drug pipeline. Ardea Biosciences‘ drug lesinurad is viewed as stronger than competitors like BioCryst and produces response rates between 70 percent […]
Amidst calls by shareholders for a management shakeup, AstraZeneca (NYSE: AZN) CEO David Brennen sought to reassert his position in an interview with Bloomberg at the Pharmaceutical Research and Manufacturers of America’s annual meeting in Boston. He said the company would not need to have a merger to effect changes at the British pharmaceutical company. […]
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
AstraZeneca (NYSE:AZN) and Amgen (NYSE:AMGN) will collaborate on five monoclonal antibodies to treat inflammatory diseases in a move that could help AstraZeneca steer away from the patent cliff and put recent setbacks behind. The pharmaceutical companies will jointly develop and commercialize five Amgen drugs. AstraZeneca will pay an initial $50 million up front and shoulder […]
In evaluating the new warning U.S. regulators are issuing on statin prescription labels, many physicians are likely to take the view that high cholesterol poses a greater risk to their patients than potential side effects like diabetes, memory loss and muscle pain. In an interview with Reuters, Steven Nissen, the head of cardiology with the […]
GlaxoSmithKline (NYSE:GSK) released fourth-quarter 2011 and full-year financial results Tuesday, which happens to be Charles Dickens’ birthday. Somehow I think it’s fitting that Britain’s largest pharmaceutical company discussed its finances on the same day that one of its greatest writers was born. GSK’s results and outlook mark a strong contrast to Britain’s second-largest pharma company, […]
AstraZeneca (NYSE:AZN) is cutting more than 7,300 jobs across its global operations as part of a restructuring move the pharmaceutical giant announced in its fourth-quarter earnings for 2012. A spokesman for the company confirmed the 7,300 in cuts spread over the next two years could impact some positions at its U.S. headquarters in Wilmington, Delaware. […]
This webinar will explore how a banking platform approach could be the resource for your company.
Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca’s (NYSE:AZN) jointly developed treatment for type 2 diabetes has been turned down by U.S. regulators until lingering questions over the diabetes drug’s benefits and risks are addressed. The U.S. Food and Drug Administration has requested additional clinical data on dapagliflozin to better assess the benefit-risk profile for the drug, including […]
Targacept (NASDAQ:TRGT) has seen two phase 3 clinical trial failures in the last two months for its depression drug candidate. Now the company has some better news, albeit for a different indication. Drug partner AstraZeneca (NYSE:AZN) will take on a Targacept Alzheimer’s disease drug candidate for further clinical studies. AstraZeneca will conduct and fund phase […]
Neoprobe‘s (NYSE Amex:NEOP) newly licensed drug candidate that could aid in the diagnosis of Alzheimer’s disease has a potential worldwide market of more than $1 billion, a company official said. Further, Dublin, Ohio-based Neoprobe expects to secure a “significant portion” of that market if and when the drug is commercialized, said Thomas Tulip, Neoprobe’s chief […]
Neoprobe (NYSE Amex:NEOP) has licensed from AstraZeneca (NYSE:AZN) the worldwide rights to an imaging drug candidate that could aid in the diagnosis of Alzheimer’s disease. Neoprobe said it plans to begin a phase 3 clinical program involving the radiopharmaceutical imaging agent, called AZD4694, in early 2013, according to a statement from the Dublin, Ohio-based company. […]
Pharmaceutical companies on Facebook for years have had a decidedly one-way relationship on the social networking site: Pharmas could post about their drugs, but the public could not write on pharma’s walls. Now that’s changed. Facebook will no longer allow pharmaceutical companies to block comments, a healthcare social media policy change that has led some […]